Alexander Disease

1. Disease Information

1.1 What is the disease?

AxD is a primary astrocyte disorder and leukodystrophy caused by pathogenic variants in GFAP, characterized by progressive neurologic dysfunction and distinctive neuroimaging and neuropathology. Multiple sources define AxD as genetic, rare, progressive/ultimately fatal, and GFAP-driven. (lynch2025diagnosingalexanderdisease pages 1-1, hagemann2022alexanderdiseasemodels pages 1-2, grossi2024asystematicreview pages 1-2)

Direct abstract-quote evidence (overview): - “Alexander disease (AxD) is a rare leukodystrophy caused by dominant gain-of-function mutations in the gene encoding the astrocyte intermediate filament, glial fibrillary acidic protein (GFAP).” (Neurological Sciences; Apr 2024) (ashton2024plasmaconcentrationsof pages 1-2) - “Alexander disease (AxD) is caused by heterozygous missense mutations in GFAP…” (Cells; Mar 2023) (hagemann2023stat3drivesgfap pages 1-2)

1.2 Key identifiers and synonyms

A consolidated identifiers/synonyms table is provided below.

Table: This table summarizes the core disease identifiers, naming conventions, causal gene, and inheritance pattern for Alexander disease from the retrieved evidence. It is useful as a compact normalization reference for a disease knowledge base entry.

Notes on evidence gaps: MONDO ID, Orphanet ORPHA code, ICD-10/ICD-11, and MeSH identifiers were not present in the retrieved full-text evidence corpus; thus they are not asserted here. (artifact-00)

1.3 Evidence provenance (patient-level vs aggregated)

The retrieved evidence includes: - Aggregated disease-level syntheses (systematic review/meta-analysis through 2023; mechanistic/clinical reviews). (grossi2024asystematicreview pages 1-2, hagemann2022alexanderdiseasemodels pages 1-2) - Patient-level clinical case material (e.g., adolescent/adult-onset diagnostic journey papers; neonatal case report). (smołka2025progressivespasticparaparesis pages 7-9, grossi2024asystematicreview pages 1-2) - Cohort studies/registries and natural history infrastructure via ClinicalTrials.gov. (NCT02714764 chunk 1, messing2025genotypephenotypeassociationfor pages 1-2)

2. Etiology

2.1 Primary causal factors

Genetic cause (core): Pathogenic variants in GFAP cause AxD/ALXDRD, typically as heterozygous dominant gain-of-function missense variants, with Rosenthal fibre formation and astrocyte stress responses. (grossi2024asystematicreview pages 1-2, hagemann2022alexanderdiseasemodels pages 1-2)

Variant spectrum (recent aggregate): A 2024 systematic review/meta-analysis collected ~550 predominantly missense causative GFAP variants through the end of 2023 and emphasized variable expressivity and incomplete genotype–phenotype clarity. (Scientific Reports; Oct 2024) (grossi2024asystematicreview pages 1-2)

2.2 Risk factors

For a Mendelian disorder, the dominant “risk factor” is carrying a pathogenic GFAP variant.

De novo occurrence is common, especially in early-onset disease: The 2024 systematic review reports frequent arginine substitutions, “mostly de novo” and more prevalent in early-onset forms. (grossi2024asystematicreview pages 1-2)

Potential (non-causal) environmental/clinical modifiers: A 2025 review notes possible adult disease contributors/precipitants such as trauma/injury, infection, or alcohol exposure; this should be interpreted cautiously because such factors are not established primary causes. (zavala2025alexandersdiseasepotential pages 1-3)

2.3 Protective factors

No validated protective genetic variants or environmental protective factors were identified in the retrieved evidence.

2.4 Gene–environment interactions

No robust gene–environment interaction evidence was identified in the retrieved evidence.

3. Phenotypes

3.1 Clinical phenotypes by age-of-onset and type

A structured phenotype table (with suggested HPO terms) is provided below.

Table: This table summarizes the clinical spectrum of Alexander disease by age-of-onset and by Type I/Type II classification, including hallmark symptoms, MRI patterns, suggested HPO mappings, and prognostic notes. It is useful for disease knowledge base curation and phenotype normalization.

3.2 Adult-onset diagnostic criteria and phenotype frequencies (from adult-onset literature)

An adult-onset case/literature synthesis notes that adult-onset AxD commonly presents with progressive spastic paraparesis and variable bulbar/cerebellar signs and cites Yoshida et al. criteria requiring onset after 12 years plus at least one neurological and one radiological medulla/cervical-spine feature. It also reports phenotype variability including asymmetry (~35%) and dementia/rigidity (~25–29%) in reviewed adult cohorts. (smołka2025progressivespasticparaparesis pages 7-9)

3.3 Quality of life impact

Direct disease-specific QoL utilities were not identified in the retrieved evidence corpus; however, the AxD natural history outcomes study explicitly collects multiple QoL instruments (e.g., EQ-5D-5L, PROMIS, PedsQL) longitudinally, enabling future quantification. (NCT02714764 chunk 1)

4. Genetic / Molecular Information

4.1 Causal gene(s)

• GFAP (glial fibrillary acidic protein) is the causal gene, with pathogenic variants producing dominant toxic effects in astrocytes. (grossi2024asystematicreview pages 1-2, hagemann2022alexanderdiseasemodels pages 1-2)

4.2 Pathogenic variant types and consequences

• Most reported disease-causing variants are heterozygous (autosomal dominant). (grossi2024asystematicreview pages 1-2)
• Variants are predominantly missense and act through toxic gain-of-function, with aggregation and astrocyte stress responses; both mutant and wild-type GFAP can be sequestered into aggregates (supporting a “sequestration hypothesis”). (grossi2024asystematicreview pages 1-2, hagemann2022alexanderdiseasemodels pages 1-2)

4.3 Modifier mechanisms and isoforms

• A Type II AxD mechanism involving splicing errors and overexpression of an uncharacterized GFAP isoform has been described (important for test design/variant interpretation). (messing2025genotypephenotypeassociationfor pages 8-8)
• Defective splicing is postulated as a contributor to age-of-onset variability in meta-analysis. (grossi2024asystematicreview pages 1-2)

4.4 Epigenetics / chromosomal abnormalities

No established epigenetic disease mechanism or recurrent chromosomal abnormality was identified in the retrieved evidence.

5. Environmental Information

No confirmed environmental causes were identified in the retrieved evidence; AxD is primarily genetic. A 2025 review notes possible adult contributory factors (trauma/infection/alcohol), but these are not established causal exposures. (zavala2025alexandersdiseasepotential pages 1-3)

6. Mechanism / Pathophysiology

6.1 Core causal chain (current understanding)

1) GFAP pathogenic variant → 2) altered intermediate filament assembly/solubility and GFAP accumulation → 3) astrocyte stress programs and reactive astrogliosis (often further increasing GFAP) → 4) formation of Rosenthal fibres → 5) downstream effects on myelin/white matter integrity and neuronal network function → clinical neurologic decline and characteristic MRI patterns. (hagemann2022alexanderdiseasemodels pages 1-2, hagemann2021antisensetherapyina pages 1-3)

6.2 Rosenthal fibres: composition and localization

A 2022 mechanistic synthesis describes Rosenthal fibres as eosinophilic inclusions in astrocytes that contain GFAP along with stress-related proteins (e.g., αB-crystallin), vimentin, ubiquitin, plectin, cyclin D2, and stress-granule–related proteins, and notes they are prominent in subpial/perivascular/periventricular astrocytes—providing a mechanistic link to periventricular MRI signal patterns. (hagemann2022alexanderdiseasemodels pages 1-2)

6.3 2023–2024 mechanistic developments

(A) STAT3 as an upstream driver of GFAP accumulation (2023): A 2023 study in a GFAP-mutant mouse model identified STAT3 as a key transcriptional driver of increased Gfap expression and GFAP accumulation. Importantly, astrocyte/conditional Stat3 reduction reversed GFAP accumulation and aggregation even in adult mice with established pathology, supporting the idea that upstream transcriptional control is therapeutically actionable. (Cells; 2023-03; https://doi.org/10.3390/cells12070978) (hagemann2023stat3drivesgfap pages 1-2)

Direct abstract-quote evidence (therapeutic implication): “These results suggest that pharmacological inhibition of STAT3 could potentially reduce GFAP toxicity…” (hagemann2023stat3drivesgfap pages 1-2)

(B) Microglial P2Y12 signaling as a protective disease modifier (2024): A 2024 Brain paper used an AxD mouse model (human GFAP R239H) and single-cell RNA-seq among other approaches to show that AxD astrocytes have reduced expression of Entpd2 (encoding the ATP-degrading enzyme NTPDase2), increasing extracellular ATP persistence. Microglia respond via P2Y12 receptor–dependent Ca2+ signaling, and pharmacologic blockade (clopidogrel) exacerbated pathology, supporting a protective microglial modifier role that may contribute to clinical diversity. (Brain; 2024-11; https://doi.org/10.1093/brain/awad358) (saito2024microgliasenseastrocyte pages 1-2)

6.4 Suggested ontology mappings

Cell types (Cell Ontology, CL): - Astrocyte: CL:0000127 (primary affected cell type implied throughout) (hagemann2022alexanderdiseasemodels pages 1-2, saito2024microgliasenseastrocyte pages 1-2) - Microglia: CL:0000129 (modifier/protective role in 2024 Brain study) (saito2024microgliasenseastrocyte pages 1-2)

Biological processes (GO suggestions; not asserted as curated annotations): - Intermediate filament organization (GO:0045109) - Protein aggregation (GO:0070848) - Astrocyte activation / gliosis (e.g., “reactive astrogliosis” concept) (hagemann2023stat3drivesgfap pages 1-2, hagemann2022alexanderdiseasemodels pages 1-2) - JAK-STAT cascade (GO:0007259) (STAT3-driven effects) (hagemann2023stat3drivesgfap pages 1-2) - Purinergic signaling / response to extracellular ATP (conceptual; P2Y12-mediated microglial sensing) (saito2024microgliasenseastrocyte pages 1-2)

Anatomy (UBERON suggestions): - Brainstem/medulla oblongata: UBERON:0001896 - Cervical spinal cord: UBERON:0002726 - Cerebral white matter: UBERON:0002302

7. Anatomical Structures Affected

7.1 Organ/system level

The central nervous system is the primary affected system. Type I often shows cerebral/forebrain-predominant involvement, while Type II often shows medulla/upper cervical spinal cord and hindbrain predominance. (hagemann2022alexanderdiseasemodels pages 1-2, grossi2024asystematicreview pages 1-2)

7.2 Tissue/cell level

AxD is a primary disorder of astrocytes (GFAP-expressing glia), with secondary effects on white matter/myelin and broader neuroinflammation involving microglia. (hagemann2022alexanderdiseasemodels pages 1-2, saito2024microgliasenseastrocyte pages 1-2, hagemann2021antisensetherapyina pages 1-3)

8. Temporal Development

8.1 Onset

Age-of-onset categories used in aggregated and registry work include neonatal (<30 days), infantile (31 days–<2 years), juvenile (2–<13 years), and adult (≥13 years). (waldman2026characterizationofclinical pages 2-3)

8.2 Progression patterns

• Early-onset (Type I/cerebral) disease is generally more severe and rapidly progressive. (hagemann2022alexanderdiseasemodels pages 1-2)
• Adult-onset (Type II/bulbospinal) presentations can be slowly progressive and diagnostically challenging due to heterogeneous symptoms. (lynch2025diagnosingalexanderdisease pages 1-1, smołka2025progressivespasticparaparesis pages 7-9)

9. Inheritance and Population

9.1 Inheritance

Most AxD cases arise from heterozygous GFAP pathogenic variants consistent with autosomal dominant inheritance, with many variants occurring de novo (particularly among recurrent arginine substitutions and early-onset phenotypes). (grossi2024asystematicreview pages 1-2)

9.2 Epidemiology (prevalence/incidence)

High-quality prevalence estimates were limited in the retrieved evidence. A 2025 review cites that “the only population-based prevalence was estimated at one in 2.7 million,” referencing prior work. (zavala2025alexandersdiseasepotential pages 1-3)

Important context from population genetics (beyond 2024 window): A 2025 UK Biobank analysis (not 2023–2024 but relevant for underdiagnosis) reported a pathogenic/likely pathogenic GFAP variant carrier frequency of ~1 in 4435 and modeled prevalence 6.8 per 100,000, interpreting this as possible underdiagnosis or reduced penetrance. (zavala2025alexandersdiseasepotential pages 1-3)

10. Diagnostics

10.1 Clinical + neuroimaging diagnosis

Adult-onset AxD can be difficult to diagnose clinically because symptoms are heterogeneous and non-specific; diagnosis typically requires clinical evaluation, characteristic neuroimaging, and confirmatory genetic testing. (lynch2025diagnosingalexanderdisease pages 1-1)

10.2 Characteristic MRI patterns (adult-onset)

Adult-onset AxD is classically associated with medullary and upper cervical spinal cord abnormalities (T2 signal change and atrophy). A key measurement-based approach includes medulla-to-pons ratio and cervical cord diameter. (smołka2025progressivespasticparaparesis pages 7-9)

Visual evidence (MRI measurement example): the adult-onset case paper includes imaging demonstrating a medulla-to-pons ratio (0.51) and cervical spinal cord diameter at C2 (5.28 mm), illustrating the measurement approach used in the literature. (smołka2025progressivespasticparaparesis media 13fab325)

10.3 Neuropathology

Rosenthal fibres within astrocytes are a defining neuropathologic hallmark across AxD forms. (hagemann2022alexanderdiseasemodels pages 1-2, grossi2024asystematicreview pages 1-2)

10.4 Genetic testing strategy (real-world)

• Because GFAP is the causal gene and clinical presentation can be non-specific—especially in adults—comprehensive gene testing approaches (e.g., exome sequencing) are used in practice to resolve unexplained progressive spastic paraparesis/ataxia/bulbar syndromes and confirm AxD via GFAP variant detection. (smołka2025progressivespasticparaparesis pages 7-9)

10.5 Differential diagnosis

Detailed differential diagnosis lists were not available in the retrieved evidence corpus; however, adult-onset AxD overlaps clinically with other adult-onset leukodystrophies and brainstem/spinal-predominant neurodegenerative syndromes, motivating reliance on MRI patterns and confirmatory genetics. (lynch2025diagnosingalexanderdisease pages 1-1, smołka2025progressivespasticparaparesis pages 7-9)

11. Outcome / Prognosis

Quantitative survival estimates stratified by subtype were not captured in the retrieved evidence corpus. Early-onset forms are repeatedly characterized as more severe with premature death, while adult-onset forms may progress more slowly but remain disabling and ultimately serious. (hagemann2022alexanderdiseasemodels pages 1-2, lynch2025diagnosingalexanderdisease pages 1-1, smołka2025progressivespasticparaparesis pages 7-9)

12. Treatment

12.1 Current standard of care (real-world)

No disease-modifying therapy is established; care is supportive/symptomatic (e.g., seizure management, mobility/rehabilitation, dysphagia management). This is explicitly noted in mechanistic and biomarker studies and in recent clinical reviews. (hagemann2021antisensetherapyina pages 1-3, saito2024microgliasenseastrocyte pages 1-2, lynch2025diagnosingalexanderdisease pages 1-1)

12.2 Emerging disease-modifying therapies

(A) GFAP-lowering antisense oligonucleotides (ASOs)

Preclinical (landmark translational study): A rat model study showed that a single intracerebroventricular dose of a Gfap-targeted ASO reduced GFAP transcript/protein to near-undetectable levels and could reverse GFAP pathology, white matter deficits, and motor impairment. Critically, the model exhibited mortality (“about 14% dying…between 6 and 12 weeks of age”), enabling functional rescue assessment. (Science Translational Medicine; 2021-11; https://doi.org/10.1126/scitranslmed.abg4711) (hagemann2021antisensetherapyina pages 1-3)

Direct abstract-quote evidence (preclinical efficacy): “a single treatment with Gfap-targeted ASO provides long-lasting suppression, reverses GFAP pathology…” (hagemann2021antisensetherapyina pages 1-3)

Clinical translation (zilganersen / ION373): A combined Phase 1–3 randomized, double-blind, placebo-controlled, multi-center trial is registered as NCT04849741. - Design: multiple-ascending dose; 2:1 randomization; 60-week double-blind + open-label and long-term extension. (NCT04849741 chunk 1) - Intervention: intrathecal bolus zilganersen (ION373) every 12 weeks through Week 49. (NCT04849741 chunk 1) - Enrollment: 54; Start date: 2021-06-01; Primary completion: 2025-08-22; Estimated completion: 2029-09; Status: active not recruiting (per retrieved record). (NCT04849741 chunk 1) - Primary endpoint: percent change from baseline in 10-Meter Walk Test at Week 61. (NCT04849741 chunk 1)

URL: https://clinicaltrials.gov/study/NCT04849741 (NCT04849741 chunk 1)

(B) STAT3/JAK-STAT pathway modulation (repurposing logic)

Mouse genetic data support STAT3 as a driver of GFAP accumulation and astrocyte pathology and argue that brain-penetrant JAK/STAT inhibitors could be explored as a strategy to lower GFAP toxicity. This is preclinical mechanistic evidence rather than clinical efficacy. (hagemann2023stat3drivesgfap pages 1-2)

(C) Microglia-targeted considerations

The 2024 Brain study suggests that inhibiting microglial P2Y12 signaling may worsen pathology in the model (clopidogrel exacerbation), raising caution about certain anti-platelet/microglial-modulating strategies and suggesting microglia may be protective modifiers. This is mechanistic animal-model evidence. (saito2024microgliasenseastrocyte pages 1-2)

12.3 Supportive interventions captured in trials infrastructure

The AxD natural history/outcome metrics study NCT02714764 (Children’s Hospital of Philadelphia; observational; started 2016-01-26; estimated enrollment 200; recruiting) collects longitudinal motor, speech/swallowing, neurocognitive, and QoL outcomes and optional blood/CSF specimens (including GFAP levels), supporting real-world evaluation of supportive care and future trial readiness. (NCT02714764 chunk 1)

URL: https://clinicaltrials.gov/study/NCT02714764 (NCT02714764 chunk 1)

12.4 Suggested MAXO terms (examples; not asserted as curated annotations)

• Intrathecal drug administration (MAXO:0000431)
• Antisense oligonucleotide therapy (MAXO concept; specific ID not in retrieved evidence)
• Physical therapy/rehabilitation (MAXO concept)
• Seizure management with antiseizure medication (MAXO concept)

13. Prevention

Primary prevention is not currently feasible because AxD is genetic; prevention strategies focus on genetic counseling and early diagnosis. Early recognition is increasingly emphasized because clinical trials of potential disease-modifying therapy are underway. (lynch2025diagnosingalexanderdisease pages 1-1, NCT04849741 chunk 1)

14. Other Species / Natural Disease

A naturally occurring “Rosenthal fiber encephalopathy in a dog resembling Alexander disease in humans” appears in search results but was not obtainable as full text within the retrieved evidence set; therefore, no claims are made here. (unobtainable listing in tool output; not citable)

15. Model Organisms

15.1 Rodent genetic models

• Rat model (GFAP mutant): Developed to better recapitulate human leukodystrophy features (white matter deficits, motor impairment). Demonstrated ASO reversibility and measurable mortality (~14% between 6–12 weeks), enabling functional studies. (hagemann2021antisensetherapyina pages 1-3)
• Mouse models (GFAP mutant): Widely used; 2023 work demonstrates manipulation of STAT3 in GFAP-expressing cells to reverse GFAP aggregation and reactive signatures. (hagemann2023stat3drivesgfap pages 1-2)
• Mouse model for immune modifier work: human GFAP R239H (60TM) used for microglial Ca2+ signaling and scRNA-seq, showing P2Y12-dependent protective microglia. (saito2024microgliasenseastrocyte pages 1-2)

15.2 Model utility and limitations (as supported by retrieved evidence)

Mouse models have been described as having Rosenthal fibres and astrogliosis but often “mild phenotype” without apparent leukodystrophy/overt clinical features, motivating the rat model for translational endpoints. (hagemann2021antisensetherapyina pages 1-3)

Recent developments (prioritizing 2023–2024) and key statistics/data

1) STAT3 mechanistic driver (2023): Conditional Stat3 reduction prevented or reversed GFAP accumulation/aggregation and lowered reactive astrocyte and microglial activation markers in AxD mouse models, highlighting upstream regulatory control of GFAP. (Hagemann et al., Cells; 2023-03-xx; https://doi.org/10.3390/cells12070978) (hagemann2023stat3drivesgfap pages 1-2)

2) Microglial P2Y12 protective modifier (2024): Single-cell RNA-seq and functional imaging in AxD model mice support a protective microglial response driven by extracellular ATP and P2Y12 signaling; clopidogrel exacerbated pathology in the model. (Saito et al., Brain; 2024-11; https://doi.org/10.1093/brain/awad358) (saito2024microgliasenseastrocyte pages 1-2)

3) Variant aggregation (2024): Systematic review/meta-analysis compiled 550 causative GFAP variants (mostly missense) and reported higher-than-expected adult cases; arginine substitutions were frequently de novo and enriched in early-onset phenotypes. (Grossi et al., Scientific Reports; 2024-10; https://doi.org/10.1038/s41598-024-75383-4) (grossi2024asystematicreview pages 1-2)

4) Fluid biomarkers cohort (2024): Plasma biomarker study: AxD n=49 vs controls n=31; neonatal n=3, infantile n=21, juvenile n=12, adult n=13; “GFAP is elevated in plasma of all age groups afflicted by AxD.” (Ashton et al., Neurological Sciences; 2024-04; https://doi.org/10.1007/s10072-024-07495-8) (ashton2024plasmaconcentrationsof pages 1-2)

5) Clinical trial readiness and implementation: Interventional ASO trial NCT04849741 (zilganersen/ION373) includes double-blind placebo control and objective functional endpoints (10MWT) with enrollment 54. Observational natural history trial NCT02714764 is recruiting with estimated enrollment 200 and captures standardized functional and QoL outcomes plus optional blood/CSF biomarkers over up to 10 years. (NCT04849741 chunk 1, NCT02714764 chunk 1)

Limitations of this report (evidence constraints)

• Curated ontology identifiers (MONDO/Orphanet/MeSH/ICD) were not present in the retrieved full text; they are therefore not asserted.
• Several key older “foundational” clinical genetics papers (e.g., Li et al. 2005 Ann Neurol initial GFAP discovery) were not retrieved in full text, so foundational PMIDs could not be provided from the evidence set.
• Detailed differential diagnosis lists and survival curves by subtype were not available in the retrieved evidence corpus.

Key URLs (from retrieved evidence)

• Grossi et al. 2024 (systematic review/meta-analysis): https://doi.org/10.1038/s41598-024-75383-4 (grossi2024asystematicreview pages 1-2)
• Hagemann et al. 2023 (STAT3 mechanism): https://doi.org/10.3390/cells12070978 (hagemann2023stat3drivesgfap pages 1-2)
• Saito et al. 2024 (microglia/P2Y12): https://doi.org/10.1093/brain/awad358 (saito2024microgliasenseastrocyte pages 1-2)
• Ashton et al. 2024 (plasma biomarkers): https://doi.org/10.1007/s10072-024-07495-8 (ashton2024plasmaconcentrationsof pages 1-2)
• NCT04849741 (zilganersen/ION373): https://clinicaltrials.gov/study/NCT04849741 (NCT04849741 chunk 1)
• NCT02714764 (natural history/outcome metrics): https://clinicaltrials.gov/study/NCT02714764 (NCT02714764 chunk 1)

References

1. (hagemann2023stat3drivesgfap pages 1-2): Tracy L. Hagemann, Sierra Coyne, Alder Levin, Liqun Wang, Mel B. Feany, and Albee Messing. Stat3 drives gfap accumulation and astrocyte pathology in a mouse model of alexander disease. Cells, 12:978, Mar 2023. URL: https://doi.org/10.3390/cells12070978, doi:10.3390/cells12070978. This article has 20 citations.

2. (saito2024microgliasenseastrocyte pages 1-2): Kozo Saito, Eiji Shigetomi, Youichi Shinozaki, Kenji Kobayashi, Bijay Parajuli, Yuto Kubota, Kent Sakai, Miho Miyakawa, Hiroshi Horiuchi, Junichi Nabekura, and Schuichi Koizumi. Microglia sense astrocyte dysfunction and prevent disease progression in an alexander disease model. Brain, 147:698-716, Nov 2024. URL: https://doi.org/10.1093/brain/awad358, doi:10.1093/brain/awad358. This article has 23 citations and is from a highest quality peer-reviewed journal.

3. (hagemann2021antisensetherapyina pages 1-3): Tracy L. Hagemann, Berit Powers, Ni-Hsuan Lin, Ahmed F. Mohamed, Katerina L. Dague, Seth C. Hannah, Gemma Bachmann, Curt Mazur, Frank Rigo, Abby L. Olsen, Mel B. Feany, Ming-Der Perng, Robert F. Berman, and Albee Messing. Antisense therapy in a rat model of alexander disease reverses gfap pathology, white matter deficits, and motor impairment. Science Translational Medicine, Nov 2021. URL: https://doi.org/10.1126/scitranslmed.abg4711, doi:10.1126/scitranslmed.abg4711. This article has 62 citations and is from a highest quality peer-reviewed journal.

4. (ashton2024plasmaconcentrationsof pages 1-2): Nicholas J. Ashton, Guglielmo Di Molfetta, Kübra Tan, Kaj Blennow, Henrik Zetterberg, and Albee Messing. Plasma concentrations of glial fibrillary acidic protein, neurofilament light, and tau in alexander disease. Neurological Sciences, 45:4513-4518, Apr 2024. URL: https://doi.org/10.1007/s10072-024-07495-8, doi:10.1007/s10072-024-07495-8. This article has 7 citations and is from a peer-reviewed journal.

5. (lynch2025diagnosingalexanderdisease pages 1-1): David S Lynch, Charles Wade, Alise K. Carlson, Frederik Barkhof, Tomokatsu Yoshida, Abigail Collins, Michael R Edwards, and A. T. Waldman. Diagnosing alexander disease in adults. Practical Neurology, pages pn-2024-004490, May 2025. URL: https://doi.org/10.1136/pn-2024-004490, doi:10.1136/pn-2024-004490. This article has 2 citations and is from a peer-reviewed journal.

6. (hagemann2022alexanderdiseasemodels pages 1-2): Tracy L. Hagemann. Alexander disease: models, mechanisms, and medicine. Current Opinion in Neurobiology, 72:140-147, Feb 2022. URL: https://doi.org/10.1016/j.conb.2021.10.002, doi:10.1016/j.conb.2021.10.002. This article has 60 citations and is from a peer-reviewed journal.

7. (grossi2024asystematicreview pages 1-2): Alice Grossi, Francesca Rosamilia, Silvia Carestiato, Ettore Salsano, Isabella Ceccherini, and Tiziana Bachetti. A systematic review and meta-analysis of gfap gene variants in alexander disease. Scientific Reports, Oct 2024. URL: https://doi.org/10.1038/s41598-024-75383-4, doi:10.1038/s41598-024-75383-4. This article has 14 citations and is from a peer-reviewed journal.

8. (NCT04849741 chunk 1): A Study to Evaluate the Safety and Efficacy of Zilganersen (ION373) in Patients With Alexander Disease (AxD). Ionis Pharmaceuticals, Inc.. 2021. ClinicalTrials.gov Identifier: NCT04849741

9. (NCT04849741 chunk 2): A Study to Evaluate the Safety and Efficacy of Zilganersen (ION373) in Patients With Alexander Disease (AxD). Ionis Pharmaceuticals, Inc.. 2021. ClinicalTrials.gov Identifier: NCT04849741

10. (NCT02714764 chunk 1): Evaluation of Outcome Metrics in Alexander Disease. Children's Hospital of Philadelphia. 2016. ClinicalTrials.gov Identifier: NCT02714764

11. (waldman2026characterizationofclinical pages 2-3): Amy T. Waldman, Asako Takanohashi, Joshua Y. Joung, Geraldine W. Liu, Kaley Arnold, Amy Pizzino, Walter Faig, Sarah Woidill, Sona Narula, and Adeline L. Vanderver. Characterization of clinical phenotype to glial fibrillary acidic protein concentrations in alexander disease. Annals of Clinical and Translational Neurology, Jan 2026. URL: https://doi.org/10.1002/acn3.70305, doi:10.1002/acn3.70305. This article has 0 citations and is from a peer-reviewed journal.

12. (smołka2025progressivespasticparaparesis pages 7-9): Katarzyna Anna Smółka, Leon Smółka, Wiesław Guz, Emilia Chaber, and Lidia Perenc. Progressive spastic paraparesis as the dominant manifestation of adolescent-onset alexander disease: case report and literature review. Journal of Clinical Medicine, 14:8232, Nov 2025. URL: https://doi.org/10.3390/jcm14228232, doi:10.3390/jcm14228232. This article has 0 citations.

13. (messing2025genotypephenotypeassociationfor pages 1-2): Albee Messing, Amy Tara Waldman, and Daniel M. Bolt. Genotype-phenotype association for 14 gfap variants in alexander disease. Neurology: Genetics, Jun 2025. URL: https://doi.org/10.1212/nxg.0000000000200270, doi:10.1212/nxg.0000000000200270. This article has 6 citations.

14. (zavala2025alexandersdiseasepotential pages 1-3): Emily Zavala and Tahl Zimmerman. Alexander's disease: potential drug targets and future directions. Molecular neurobiology, May 2025. URL: https://doi.org/10.1007/s12035-025-05083-1, doi:10.1007/s12035-025-05083-1. This article has 0 citations and is from a peer-reviewed journal.

15. (smołka2025progressivespasticparaparesis pages 13-14): Katarzyna Anna Smółka, Leon Smółka, Wiesław Guz, Emilia Chaber, and Lidia Perenc. Progressive spastic paraparesis as the dominant manifestation of adolescent-onset alexander disease: case report and literature review. Journal of Clinical Medicine, 14:8232, Nov 2025. URL: https://doi.org/10.3390/jcm14228232, doi:10.3390/jcm14228232. This article has 0 citations.

16. (smołka2025progressivespasticparaparesis media 13fab325): Katarzyna Anna Smółka, Leon Smółka, Wiesław Guz, Emilia Chaber, and Lidia Perenc. Progressive spastic paraparesis as the dominant manifestation of adolescent-onset alexander disease: case report and literature review. Journal of Clinical Medicine, 14:8232, Nov 2025. URL: https://doi.org/10.3390/jcm14228232, doi:10.3390/jcm14228232. This article has 0 citations.

17. (messing2025genotypephenotypeassociationfor pages 8-8): Albee Messing, Amy Tara Waldman, and Daniel M. Bolt. Genotype-phenotype association for 14 gfap variants in alexander disease. Neurology: Genetics, Jun 2025. URL: https://doi.org/10.1212/nxg.0000000000200270, doi:10.1212/nxg.0000000000200270. This article has 6 citations.